Form 4: Forte Biosciences Insider Trades: Wagner Acquires RSUs

Paul A. Wagner, Director and Officer of Forte Biosciences, Inc., acquired 1,250 Restricted Stock Units (RSUs) on July 1, 2026, as detailed in a Form 4 filing.

Summary

• Paul A. Wagner, who holds positions as Director, Officer, CEO, Secretary, and Chair of the Board at Forte Biosciences, Inc., reported a transaction on July 1, 2026.
• Wagner acquired 1,250 Restricted Stock Units (RSUs).
• These RSUs represent a contingent right to receive one share of Forte Biosciences, Inc. Common Stock.
• The RSUs are subject to vesting, with one-sixteenth (1/16th) vesting on each Quarterly Vesting Date (January 1, April 1, July 1, and October 1) starting February 1, 2023, provided Wagner remains a Service Provider.
• Following the transaction, Wagner beneficially owns 85,580 shares of Common Stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine insider equity awards and a small sale, rather than significant strategic shifts or financial performance indicators.

Positives

• Insider acquisition of equity awards can signal confidence in the company's future prospects.
• The acquisition of RSUs indicates a long-term incentive structure for key management.

Risks

• The vesting of RSUs is contingent on Wagner remaining a Service Provider, introducing potential retention risk.
• The value of the RSUs is tied to the performance of Forte Biosciences, Inc. Common Stock, which is subject to market volatility.

Future Outlook

The vesting schedule for the RSUs indicates a continued commitment from Paul A. Wagner to the company over the next several quarters, contingent on his continued service.

Industry Context

StockSavvy.ai notes that insider transactions, particularly the acquisition of equity awards like RSUs, are common in the biotechnology and pharmaceutical sectors as companies use them to attract and retain key talent and align management interests with shareholder value.

Stakeholder Impact

• Shareholders: The acquisition of RSUs by a key executive may be viewed positively as it aligns management's interests with long-term company performance.
• Employees: The RSU award structure highlights the company's use of equity-based compensation for its leadership team.
• Management: Paul A. Wagner's continued involvement and equity stake reinforce his role within the company.

Next Steps

• Continued vesting of RSUs for Paul A. Wagner on quarterly dates (January 1, April 1, July 1, October 1) as long as he remains a Service Provider.
• Ongoing reporting of any future changes in beneficial ownership by Paul A. Wagner.

Key Dates

Keywords

Forte Biosciences, FBRX, Form 4, Insider Trading, Restricted Stock Units, RSU, Equity Award, Beneficial Ownership, Paul A. Wagner, SEC Filing